Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/3/2019
SIETES contiene 92698 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Taylor P. GSK, J&J say monthly injection keeps HIV controlled. PMLiVE 2019:8 de marzo. [Ref.ID 103051]
3. Cita con resumen
Taylor P. Trump’s Brexit trade plan is bad for NHS, say campaigners. PMLiVE 2019:4 de marzo. [Ref.ID 103046]
4. Cita con resumen
Taylor P. Novartis back in the spotlight over Trump/Cohen links. PMLiVE 2019:28 de febrero. [Ref.ID 103043]
5. Cita con resumen
Taylor P. Finch’s microbiota drug for C. diff gets FDA breakthrough status. PMLiVE 2019:11 de febrero. [Ref.ID 103019]
7. Cita con resumen
Taylor P. AbbVie’s blockbuster-in-waiting for endometriosis gets FDA nod. PMLiVE 2018:25 de julio. [Ref.ID 102723]
8. Cita con resumen
Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet 2016;388:239-47. [Ref.ID 100631]
9. Cita con resumen
Taylor P, Nutt D, Fortson R, Henderson G, on behalf of DrugScience. Ketamine—the real perspective. Lancet 2016;387:1271-2. [Ref.ID 100277]
10. Cita con resumen
Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011;70:1895-904. [Ref.ID 91109]
Seleccionar todas
 
 1 a 10 de 10